lricitea ‘W
`
`Journal Citation Report
`
`Essential Science Indicators -W‘
`
`EridN-)r:eT"'
`
`Signln
`
`Help
`
`English
`
`THOMSON REUTERS‘
`
`Return to Search Results
`
`My Tools
`
`Search History Marked List
`
`Fu||Tex1_opfion5 V
`
`H
`
`Save to EndNote online v
`
`Add to Marked List
`
`Citation Network
`
`145 Times Cited
`24 Cited Reterences
`View Related Records
`
`View Citation Map
`j Create Citation Alert
`(dmfafimn fvt'¢bofScria|cc7"CoreGnlIlcn‘iar1)
`
`View PuhMed Related Articles
`
`All Times cited counts
`156 in All Datahmes
`146 in Web ot Science Core Collection
`70 in BIOSIS Citation Index
`10 in Chinese Science Citation
`Database
`0 in Data Citation Index
`U in SciELO Citation Index
`
`Usage count
`Last 18!] Days: I]
`Since 2013: I]
`Learn more
`
`Most Recent citation
`
`lzzedine, Hassan. Pemetrexed
`nephrotoxicity . BULLETIN DU
`CANCER, FEB 2015.
`View All
`
`This record is from:
`MEDLINE 3
`
`Suggest a co mectio n
`If you would Ire to inpuove the quiity
`of the data ‘I1 tfls Iecord, please
`suggfit a conection,
`
`‘‘ LY231514 as first-line chemotherapy for patients with advanced non-
`small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials
`Group.
`By:
`
`J J; Eisenhauer_ E; Butts, C; Gregg. R; Dancey_ J; Fisher. B; lglesias. J
`
`Journal of clinical oncology : official journal of the American Society of Clinical Oncology
`Volume: 17 Issue: 4 Pages: 1194
`Published: 1999—Apr
`
`Abstract
`PURPOSE: To evaluate the efficacy and satety ot the-‘ LY231514 {MTAJ in patients receiving initial chemotherapy for unresectable,
`advanced non-small-cell lung cancer [NSCLC].
`
`PATIENTS AND METHODS: Patients with measurable, advanced NSCLC who had not received previous chemotherapy for advanced disease were
`considered for this study, Eligible patients who gave written intormed consent initially received MTA 600 mgfm(2] intravenorsly (IV) for 10 minutes every 3
`weeks. After three patients received treatment at this dose, the dose was reduced to 5UU mgfm(2] IV at the same infusion time and frequency because of
`toxicity seen in this study and another Canadian MTA trial in colorectal cancer. Patients received up to four cycles after complete or partial remission or six
`cycla after stable disease was documented,
`
`RESULTS: Thiny-three patients were accrued onto the study, All were assessable for toxicity, and 30 patients were assessable for mporse, All but one
`patient had an Eastern Cooperative Oncology Group performance status score of U or 1, 18 patients (55%) had adenocarcinoma, and nine patients (27%) had
`squamous cell carcinoma. Twenty-five patients (76%) had stage IV disease, and the remainder had stage IIIB disease at trial entry. Seven patients
`experienced a confirmed partial rwporse and no complete rmporsm were seen; thts, the overall rmponse rate was 23.3% (95% confidence interval, 9.9%
`to 42.3%]. The median duration ot response was 3.1 months (range, 2. 3 to 13.5 montts] after a median follow-up period ot 7.9 months. Four (67%) ot six
`patients with stage IIIB disease and three (12.5%) of 24 with stage IV disease raponded to treatment. Four patients (13.3%) experienced febrile neutropenia
`and 13 (39%) experienced grade 3 or 4 neutropenia, whereas only one patient (3%) developed grade 4 thrombocytopenia. Nonhematologic toxicity was
`generally mild or moderate, but 39% of patients developed a grade 3 skin rash. Most other toxicities comprised grade 1 or2 stomatitis, diarrhea, lethargy, and
`anorexia, Ten patients stopped protocol therapy became of toxicity,
`
`CONCLUSION: MTA seems to have clinically meaningful activity as a single agent against advanced NSCLC. Toxicity is generally mild and tolerable. Further
`study of this agent in combination with cisplatin and other active dmgs is warranted in this disease,
`
`Author Information
`Address: Hamilton Regional Cancer Centre, Hamilton, Ontario, Canada.
`
`categories I Classilication
`Research Areas: Geriatrics & Gerontology; Pharmacology & Phamracy; Rwpiratory System; Biochemistry & Molecular Biology (provided by Thomson
`Reuters]
`MeSH Tenrrs:
`
`adverse effects
`"therapeutic use
`"drug therapy
`
`adverse effects
`
`"therapeutic use
`adverse effects
`
`‘analogs & derivativa
`therapeutic Lse
`
`Heading
`Adult
`
`Aged
`Antineoplastic Agents
`
`Carcinoma. Small Cell
`Female
`Glutamates
`
`Humans
`
`Infusions, Intravenous
`
`Lung Neoplasms
`Male
`
`Middle Aged
`Survival Analysis
`Treatment Outcome
`
`Chemical:
`
`Registry Number
`
`Teva – Fresenius
`Exhibit 1034-00001
`
`
`
`Journal Citation Report
`
`Essential Science Indicators -W‘
`
`EridN-)r:eT"'
`
`Signln
`
`Help
`
`English
`
`THOMSON REUTERS‘
`
`Return to Search Results
`
`My Tools
`
`Search History Marked List
`
`Fu||Tex1_opfion5 V
`
`H
`
`Save to EndNote online v
`
`Add to Marked List
`
`Citation Network
`
`145 Times Cited
`24 Cited Reterences
`View Related Records
`
`View Citation Map
`j Create Citation Alert
`(dmfafimn fvt'¢bofScria|cc7"CoreGnlIlcn‘iar1)
`
`View PuhMed Related Articles
`
`All Times cited counts
`156 in All Datahmes
`146 in Web ot Science Core Collection
`70 in BIOSIS Citation Index
`10 in Chinese Science Citation
`Database
`0 in Data Citation Index
`U in SciELO Citation Index
`
`Usage count
`Last 18!] Days: I]
`Since 2013: I]
`Learn more
`
`Most Recent citation
`
`lzzedine, Hassan. Pemetrexed
`nephrotoxicity . BULLETIN DU
`CANCER, FEB 2015.
`View All
`
`This record is from:
`MEDLINE 3
`
`Suggest a co mectio n
`If you would Ire to inpuove the quiity
`of the data ‘I1 tfls Iecord, please
`suggfit a conection,
`
`‘‘ LY231514 as first-line chemotherapy for patients with advanced non-
`small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials
`Group.
`By:
`
`J J; Eisenhauer_ E; Butts, C; Gregg. R; Dancey_ J; Fisher. B; lglesias. J
`
`Journal of clinical oncology : official journal of the American Society of Clinical Oncology
`Volume: 17 Issue: 4 Pages: 1194
`Published: 1999—Apr
`
`Abstract
`PURPOSE: To evaluate the efficacy and satety ot the-‘ LY231514 {MTAJ in patients receiving initial chemotherapy for unresectable,
`advanced non-small-cell lung cancer [NSCLC].
`
`PATIENTS AND METHODS: Patients with measurable, advanced NSCLC who had not received previous chemotherapy for advanced disease were
`considered for this study, Eligible patients who gave written intormed consent initially received MTA 600 mgfm(2] intravenorsly (IV) for 10 minutes every 3
`weeks. After three patients received treatment at this dose, the dose was reduced to 5UU mgfm(2] IV at the same infusion time and frequency because of
`toxicity seen in this study and another Canadian MTA trial in colorectal cancer. Patients received up to four cycles after complete or partial remission or six
`cycla after stable disease was documented,
`
`RESULTS: Thiny-three patients were accrued onto the study, All were assessable for toxicity, and 30 patients were assessable for mporse, All but one
`patient had an Eastern Cooperative Oncology Group performance status score of U or 1, 18 patients (55%) had adenocarcinoma, and nine patients (27%) had
`squamous cell carcinoma. Twenty-five patients (76%) had stage IV disease, and the remainder had stage IIIB disease at trial entry. Seven patients
`experienced a confirmed partial rwporse and no complete rmporsm were seen; thts, the overall rmponse rate was 23.3% (95% confidence interval, 9.9%
`to 42.3%]. The median duration ot response was 3.1 months (range, 2. 3 to 13.5 montts] after a median follow-up period ot 7.9 months. Four (67%) ot six
`patients with stage IIIB disease and three (12.5%) of 24 with stage IV disease raponded to treatment. Four patients (13.3%) experienced febrile neutropenia
`and 13 (39%) experienced grade 3 or 4 neutropenia, whereas only one patient (3%) developed grade 4 thrombocytopenia. Nonhematologic toxicity was
`generally mild or moderate, but 39% of patients developed a grade 3 skin rash. Most other toxicities comprised grade 1 or2 stomatitis, diarrhea, lethargy, and
`anorexia, Ten patients stopped protocol therapy became of toxicity,
`
`CONCLUSION: MTA seems to have clinically meaningful activity as a single agent against advanced NSCLC. Toxicity is generally mild and tolerable. Further
`study of this agent in combination with cisplatin and other active dmgs is warranted in this disease,
`
`Author Information
`Address: Hamilton Regional Cancer Centre, Hamilton, Ontario, Canada.
`
`categories I Classilication
`Research Areas: Geriatrics & Gerontology; Pharmacology & Phamracy; Rwpiratory System; Biochemistry & Molecular Biology (provided by Thomson
`Reuters]
`MeSH Tenrrs:
`
`adverse effects
`"therapeutic use
`"drug therapy
`
`adverse effects
`
`"therapeutic use
`adverse effects
`
`‘analogs & derivativa
`therapeutic Lse
`
`Heading
`Adult
`
`Aged
`Antineoplastic Agents
`
`Carcinoma. Small Cell
`Female
`Glutamates
`
`Humans
`
`Infusions, Intravenous
`
`Lung Neoplasms
`Male
`
`Middle Aged
`Survival Analysis
`Treatment Outcome
`
`Chemical:
`
`Registry Number
`
`Teva – Fresenius
`Exhibit 1034-00001
`
`
`
`0
`0
`
`Antineuplastic Agents
`Glutam ates
`
`IMQQAIZTNO
`5Z93L87A1 R
`
`pemetrexed
`Guanine
`
`Document Information
`Document Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non—U.S. Gov-"t
`Language: English
`PubMed ID: 10561178
`NLM Unique ID: 8309333
`
`Date Created:‘ Date Completed: 07 Jan 2000
`Country: UNITED STATES
`ISSII: 0T32—183X
`
`Date Revised: 21 Nov 2013
`
`Journal Information
`Table of Contents: Current Contents Connects
`Impact Factor: Journal Citation Reponsm
`
`Other Information
`Citation Subset: Index Medicus
`Status: MEDLINE
`
`@2015 IILII.
`® 2015 THOMSON REUTERS
`
`TERMSOF USE
`
`PRIVACY POLICY
`
`FEEDBACK
`
`(«tour
`
`Teva — Fresenius
`
`Exhibit 1034-00002
`
`Teva – Fresenius
`Exhibit 1034-00002
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
